Moreover, plasma VEGF-A levels higher than 95.77 pg/mL could reflect the presence of cancer in anti-TIF1-γ antibody-positive DM patients, depicting that quantifying VEGF-A in plasma could facilitate patient identification of cancer risk among anti-TIF1-γ antibody-positive DM patients. Here, TRIM33 is linked to dermatomyositis.